MentionFox
Home › Executive changes › Cartesian Therapeutics, Inc.
Leadership changes · SEC Form 8-K, Item 5.02

Cartesian Therapeutics, Inc. executive changes

Every leadership change Cartesian Therapeutics, Inc. reported to the SEC under Item 5.02: who left, who was appointed, to what role and from when, quoted from each filing.

Filings2
Departures named1
Latest filing2026-05-26

Cartesian Therapeutics, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-05-26. Between them they name 1 person. Each change below is quoted from the filing and linked to it.

Every change, newest first

Filed 2026-05-26 · 8-K

Reported

On May 22, 2026, Milos Miljkovic, M.D., the Company's Chief Medical Officer, delivered a notice of resignation to the Company.
Filed 2026-03-30 · 8-K

Departing: Murat Kalayoglu, Director, effective 2026-03-31

On March 26, 2026, Murat Kalayoglu, M.D., Ph.D., a member of the Board of Directors (the "Board") of Cartesian Therapeutics, Inc. (the "Company"), notified the Company of his intent to resign from the Board, effective as of March 31, 2026, to pursue other opportunities.
Hiring for a seat like this?

Find people with the same kind of experience as the Director at Cartesian Therapeutics, Inc., with the record behind each one.

Find candidates like Director at Cartesian Therapeutics, Inc.
Selling to Cartesian Therapeutics, Inc.?

New leaders review vendors and budgets in their first months. Get an alert the next time Cartesian Therapeutics, Inc. is in the news or changes leadership.

Get an alert when Cartesian Therapeutics, Inc. changes leadership

Tools for this story

Each opens in a new tab, filled in for Cartesian Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/cartesian-therapeutics
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2
Cartesian Therapeutics, Inc. (RNAC) executive changes: 2 leadership filings. MentionFox, 2026-09-27. https://mentionfox.com/executive-changes/cartesian-therapeutics